University of Liverpool and IISc Bengaluru Launch Joint Seed Fund to Boost AI, Health, and Space Innovation

IMT News Desk
IMT News Desk
· 2 min read
University of Liverpool & IISc Bengaluru launch joint seed fund for AI, health, space innovation.

In a landmark move to tackle global challenges, the University of Liverpool (UK) and the Indian Institute of Science (IISc) Bengaluru have unveiled a joint seed fund aimed at accelerating research collaborations in artificial intelligence (AI), health, and space technologies.

This initiative builds on a 2023 Memorandum of Understanding (MoU) that deepened ties between the two prestigious institutions, particularly through linkages between their historic biochemistry departments among the world’s oldest. A pivotal visit by a University of Liverpool delegation to IISc in September 2025 further solidified commitments across key research domains.

The seed fund will prioritize breakthroughs in:

  • Applications of AI
  • Biomedical and Life Sciences
  • One Health/Infectious Diseases
  • Quantum Technology
  • Space

Both universities have pledged substantial annual co-investments for an initial three-year period, fueling innovative projects with real-world impact.

Beyond funding, the partnership emphasizes nurturing early-career researchers via robust PhD training programs that blend UK and Indian academic strengths, including faculty exchanges, co-supervision, bilateral symposia, and workshops.

Professor Tariq Ali, Pro-Vice-Chancellor for Global Engagement and Partnerships at the University of Liverpool, hailed the fund as a “powerful platform” uniting world-leading expertise. “Through collaboration in AI, biotechnology, health and life sciences, quantum technologies and space, while investing in the next generation, we’re strengthening research links and delivering international impact,” he said. “We eagerly anticipate the innovative ideas and enduring partnerships this will spark.”

Prof. Baladitya Suri, Chair of the Office of International Relations at IISc, echoed the sentiment: “Academic collaborations advance science, education, and innovation for societal good. This partnership fosters interdisciplinary dialogue, knowledge sharing, and sustainable engagement through joint programs.”

This India-UK alliance underscores growing momentum in cross-border research, positioning Bengaluru as a hub for AI-health-space innovation amid rising global demands.

Read Next

India’s first focused health AI Conclave unites doctors and AI experts
Featured Article
July 10, 2026

India’s first focused health AI Conclave unites doctors and AI experts

• Global Healthcare Academy hosts HAI Conclave 2026, India’s first national platform dedicated to Healthcare and Artificial Intelligence • Landmark Bengaluru conference brings together healthcare leaders and AI experts to explore how Artificial Intelligence can make healthcare faster, safer and more accessible while keeping patients at the centre of every decision The inaugural edition of the HAI Conclave […]
Article by: IMT News Desk
Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026
News
July 10, 2026

Fischer Medical Ventures Highlights NYB.AI Partnership as Platform Showcased at NVIDIA GTC Taiwan 2026

Fischer Medical Ventures Limited (FMVL) has announced that its strategic partner, Nanyang Biologics, has achieved a major international milestone with its AI-powered molecular research platform, NYB.AI, being featured in the opening showcase at NVIDIA GTC Taiwan 2026, ahead of the keynote address by NVIDIA Founder and CEO Jensen Huang. The recognition places NYB.AI among a […]
Article by: IMT News Desk
Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs
News
July 10, 2026

Pharma Q1 Margins Seen Under Pressure Despite Revenue Growth: Goldman Sachs

Indian pharmaceutical companies are expected to report healthy revenue growth in the first quarter of FY27, but margins are likely to compress as sector profitability comes under pressure. In a recent preview note, Goldman Sachs said it anticipates around 185 basis points year-on-year margin decline for the sector in the June quarter, driven primarily by […]
Article by: IMT News Desk
Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue
News
July 10, 2026

Dr Reddy’s Delays Semaglutide Supplies After Active Ingredient Quality Issue

Dr Reddy’s Laboratories has announced a delay in commercial supplies of its semaglutide product after certain batches were found to be out of specification due to an issue with the active pharmaceutical ingredient (API) used in the drug. The company said it has initiated an investigation into the root cause and is taking corrective measures […]
Article by: IMT News Desk